1. Home
  2. PNTG vs CGEM Comparison

PNTG vs CGEM Comparison

Compare PNTG & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Pennant Group Inc.

PNTG

The Pennant Group Inc.

HOLD

Current Price

$34.10

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.35

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNTG
CGEM
Founded
2019
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
904.7M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
PNTG
CGEM
Price
$34.10
$16.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
8
Target Price
$37.00
$30.13
AVG Volume (30 Days)
226.3K
956.5K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
N/A
EPS
0.24
N/A
Revenue
$947,705,000.00
N/A
Revenue This Year
$24.72
N/A
Revenue Next Year
$7.61
$5.20
P/E Ratio
$142.27
N/A
Revenue Growth
36.31
N/A
52 Week Low
$21.74
$5.68
52 Week High
$37.54
$16.74

Technical Indicators

Market Signals
Indicator
PNTG
CGEM
Relative Strength Index (RSI) 53.19 62.01
Support Level $28.05 $11.92
Resistance Level $35.13 N/A
Average True Range (ATR) 1.59 1.03
MACD -0.22 0.08
Stochastic Oscillator 24.62 89.05

Price Performance

Historical Comparison
PNTG
CGEM

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: